Top 15 Global Pharmaceutical Company Awards $1 Million in Study Extensions to eResearchTechnology for Cardiac Safety Monitoring

Top 15 Global Pharmaceutical Company Awards $1 Million in Study
Extensions to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Awards Include a Series of Late Phase Studies for Multiple Indications for Two
Key Clinical Development Programs 


PHILADELPHIA, May 17  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has been
awarded study extensions totaling approximately $1 million in cardiac safety
monitoring and services from a top 15 global pharmaceutical organization under
a previously executed Franchise agreement for two of its key drug candidates in
later phase clinical trials.

The awards cover extensions to a series of Phase II and Phase III studies that
target several indications.  eRT is already providing comprehensive support for
these studies, including provision of digital 12-lead ECG equipment designed to
facilitate collection of cardiac safety data that is subsequently provided to
eRT for analysis.  eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data through its
EXPeRT workflow-enabled data handling technology, the first solution in
production that was designed explicitly to meet emerging international
regulatory guidance and technical standards.

"eRT is pleased to be in a position to rapidly respond to the increased needs
of two of this sponsors' key clinical development programs," said Scott
Grisanti, senior vice president of business development and chief marketing
officer at eRT.  "Trial extensions are becoming more common as the new drug
development industry implements adaptive clinical trial strategies that are
designed to enable an agile response to evolving regulatory requirements and to
act on initial trial feedback while studies are still in process.  eRT's Global
Customer Care capabilities, including digital ECG equipment marshalling and
distribution, along with comprehensive site education curricula and support,
are proving critical to effectively executing significant trial extensions as
exemplified by these awards."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  These studies may be canceled by the sponsor at its sole discretion. 
As a result, actual results may differ materially from any financial outlooks
stated herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone];

or Matt Hayden, Hayden Communications, [phone], for

eResearchTechnology



Web site:  http://www.ert.com/

Copyright